Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 33c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $229.74 +7.13%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
FUSE, INM, TRI, More
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $3.22, $0.33 better than the analyst estimate of $2.89. Revenue for the quarter came in at $412 million versus the consensus estimate of $421 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2017 EPS of $10.70-$11.20, versus the consensus of $10.90. Jazz Pharmaceuticals sees FY2017 revenue of $1.6-1.65 million, versus the consensus of $1.64 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Super Micro Computer (SMCI) Tops Q1 EPS by 58c, Offers Guidance
- Accel Entertainment (ACEL) Tops Q3 EPS by 5c
- Skyworks Solutions (SWKS) Tops Q4 EPS by 1c, Beats on Revenue; Offers Q1 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
